The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESH MM 2018 | Opinion: EU approval of daratumumab plus VMP for frontline transplant-ineligible multiple myeloma
In September 2018, the European Commision authorized daratumumab for frontline use with bortezomib, melphalan, prednisolone (VMP) in newly diagnosed transplant-ineligible multiple myeloma (MM), based on the results of the ALCYONE study (NCT02195479). We spoke to the primary investigator of the study, Maria-Victoria Mateos, MD, PhD, of the University of Salamanca, Salamanca, Spain, about this development. Dr Mateos discussed how this new standard of care will affect the treatment and care of MM patients. This video was recorded at the European School of Haematology (ESH) International Conference on MM 2018, held in Mandelieu, France.
